Akt negatively regulates apoptotic pathways at a premitochondrial level through phosphorylation and modulation of proteins such as Bad, Forkhead proteins, and GSK-3␤. Akt has also been shown to protect cell death at a post-mitochondrial level, although its downstream targets have not been well documented. Here, we demonstrate that Akt, including AKT1 and AKT2, interacts with and phosphorylates X-linked inhibitor of apoptosis protein (XIAP) at residue serine-87 in vitro and in vivo. Phosphorylation of XIAP by Akt protects XIAP from ubiquitination and degradation in response to cisplatin. Moreover, autoubiquitination of XIAP is also inhibited by Akt. Consistent with this, an XIAP mutant introduced into cells which mimics the Akt-phosphorylated form (i.e. XIAP-S87D) displays reduced ubiquitination and degradation as compared with wild type XIAP. The greater stability of XIAP-S87D in cells translated to increased cell survival after cisplatin treatment. Conversely, a mutant that could not be phosphorylated by Akt (XIAP-S87A) was more rapidly degraded and showed increased cisplatin-induced apoptosis. Furthermore, suppression of XIAP by either siRNA or adenovirus of antisense of XIAP induced programmed cell death and inhibited Akt-stimulated cell survival in ovarian cancer cells. These data identify XIAP as a new downstream target of Akt and a potentially important mediator of the effect of Akt on cell survival.
tified: Akt1/PKB␣, Akt2/PKB␤, and Akt3/PKB␥, all of which are activated by growth factors in a phosphatidylinositol 3-OHkinase-dependent manner (4 -6 (Akt2), or Ser 472 (Akt3) in the C-terminal activation domain (7) .
Accumulated evidence shows that Akt and its downstream targets constitute a major cell survival pathway. Akt promotes cell survival and suppresses apoptotic death in a number of cell types induced by a variety of stimuli, including growth factor withdrawal, cell cycle discordance, and loss of cell adhesion (7) . Several downstream targets containing the Akt phosphorylation consensus sequence (R-X-R-X-X-S/T) have been identified which shed light on the mechanisms by which Akt promotes cell survival and blocks apoptosis. The first anti-apoptotic Akt target identified was the pro-apoptotic protein BAD. BAD is a pro-death member of the Bcl-2 family that initiates apoptosis by binding to Bcl-x L on the outer mitochondrial membrane, causing the release of cytochrome c into the cytosol. Akt phosphorylates BAD on Ser 136 , promoting the association of BAD with 14-3-3 proteins in the cytosol and inactivating its proapoptotic function (7) . The execution of cellular apoptosis also involves changes in the transcriptional program (7) . Akt decreases the transcription of a subset of death genes by phosphorylation of the Forkhead family of transcription factors, which causes their nuclear exclusion and inactivation (7) . Akt also phosphorylates and activates the cyclic AMP-response element-binding protein, which increases the transcription of anti-apoptotic genes, such as Bcl-2 (8, 9) . In addition, recent studies have shown that Akt phosphorylates and inactivates apoptosis signal-regulating kinase-1, a mitogen-activated protein kinase kinase kinase that mediates stress-and cytokineinduced cell death (10, 11) . Akt also phosphorylates the murine double minute-2 protein promoting its translocation to the nucleus and the destabilization of p53 (12) . By promoting the degradation of p53, Akt impairs the cellular stress response, increasing the survival of tumor cells. A role for an anti-apoptotic function of Akt at a post-mitochondrial step has also been proposed (13) , and Akt has been reported to directly phosphorylate and inactivate the cell death protease caspase-9 (14) . In addition, Akt has also been shown to inhibit the activation of Bax during apoptosis through an uncharacterized mechanism (11, 15) .
The inhibitor of apoptosis proteins (IAPs) are a family of intracellular anti-apoptotic proteins, first identified in baculovirus, which play a key role in cell survival by modulating death-signaling pathways at a post-mitochondrial level. They currently include X-linked IAP (XIAP), human IAP-1 (Hiap-1), human IAP-2 (Hiap-2), neuronal apoptosis inhibitory protein (Naip), Survivin, and Livin. These proteins are characterized by the presence of a caspase-recruitment domain and an N-terminal baculovirus-inhibitor-of-apoptosis-repeat motif, which is necessary for biological activity. With the exception of Naip and survivin, IAPs also contain a C-terminal RING-zinc finger domain believed to be involved in protein-protein and protein-nucleic acid interactions (16) . Recent studies have shown that the RING finger domain has ubiquitin protease ligase (E3) activity and is responsible for the autoubiquitination and degradation of IAPs after an apoptosis stimulus (17) . Among human IAPs, XIAP is the most potent inhibitor of caspases and apoptosis. It has been shown that XIAP is a direct inhibitor of caspase-3 and caspase-9 and modulates the Bax/ cytochrome c pathway by inhibiting caspase-9 (18) .
In the present report, we demonstrate that XIAP is a physiological substrate of Akt. Akt interacts with and phosphorylates XIAP at serine 87. Phosphorylation of XIAP by Akt inhibits both its autoubiquitination and cisplatin-induced ubiquitination. These effects reduce XIAP degradation and the increased levels of XIAP are associated with decreased cisplatin-stimulated caspase 3 activity and programmed cell death.
MATERIALS AND METHODS
Cell Lines and Transfection-The human ovarian cancer epithelial cell line A2780S and human embryonic kidney (HEK) 293 cells were cultured at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. The cells were transfected with appropriate DNA indicated in the figure legends, using LipofectAMINE Plus (Invitrogen).
Plasmid Constructs-Akt plasmids have previously been described (19, 20) . FLAG-tagged XIAP was generated by reverse transcriptase-PCR and subcloned to p3XFLAG-CMV-10 vector (Sigma). XIAP-S87A and XIAP-S87D mutant constructs were created using a QuikChange site-directed mutagenesis kit (Stratagene). Myc-tagged ubiquitin and Flg-Bcl2 constructs was kindly provided by Drs. Wenlong Bai and Gen Wang. The glutathione S-transferase (GST)-XIAP and GST-XIAPS87A were created by PCR and subcloned to pGEX-4T1.
Terminal Deoxynucleotidyltransferase-mediated dUTP Nick End Labeling (TUNEL) and Caspase-3 Activity Assays-Apoptotic cells were detected with TUNEL using an in situ cell death detection kit (Roche Applied Science). For caspase-3 activity, following cisplatin treatment, cells were harvested, lysed, and assayed with caspase-3 kit.
GST Fusion Protein, Immunoprecipitation, Immunoblotting, and in Vitro Kinase Assay-GST-XIAP fusion proteins, immunoprecipitation, and immunoblotting were performed as described previously (19, 20) . For in vitro kinase assay, Akt immunoprecipitates were incubated with a kinase buffer (19) . GST-XIAP fusion proteins were used as the exogenous substrate. Each experiment was repeated three times.
In 32 P]orthophosphate (0.5 mCi/ml) in minimum Eagle's medium without phosphate for 2 h. FLAG-XIAP was immunoprecipitated with anti-FLAG antibody. The immunoprecipitates were separated on SDS-PAGE and transferred to membranes. Phosphorylated XIAP was detected by autoradiography. Pulse-chase was performed as described previously (20) .
RESULTS
Akt Stabilizes XIAP-XIAP is a mammalian prototype of the IAP family and suppresses the programmed cell death by direct inhibition of caspase-9 and caspase-3 activity (16). Down-regulation of XIAP is an important mechanism for caspase activation in response to different apoptotic stimuli, including chemotherapeutic agents (21) . We and others (22, 23) have previously shown that cisplatin-induced programmed cell death is accompanied by a decrease in XIAP protein content. We also found that activation of the Akt pathway induces cisplatin resistance by inhibition of apoptosis (24) . Together, these findings prompted us to examine whether Akt inhibits cisplatin-induced XIAP degradation. A2780S ovarian cancer cells, which are sensitive to cisplatin, were stably transfected with constitutively active AKT2 (Myr-AKT2) or pcDNA3 vector alone (Fig. 1A) . In pcDNA3-transfected cells, cisplatin (10 and 20 M)) treatment induces a significant decline of XIAP protein expression. In contrast, XIAP levels were stable in Myr-AKT2-transfected A2780S cells (Fig. 1, B and C) . TUNEL assay analysis showed that Myr-AKT2 also protected A2780S cells from cisplatin-induced apoptois (Fig. 1C) . In addition, cisplatin-induced down-regulation of XIAP is cisplatin-dose-dependent (Fig. 1, B and C) . To determine whether Akt effects XIAP at the transcriptional level, we performed Northern blot analysis using total RNA prepared from pcDNA3-A2780S or Myr-AKT2-transfected A2780S cells following treatment with cisplatin. As shown in Fig. 1D , levels of XIAP mRNA were similar in both cell lines and not effected by cisplatin, ruling out transcriptional regulation of XIAP by cisplatin and Akt. A second possibility is that XIAP expression and its down-regulation by cisplatin treatment of cells is predominantly regulated postranslationally via a protein degradation mechanism. To test this hypothesis, we performed a pulse-chase assay. pcDNA3-A2780S and Myr-AKT2-A2780S cells were metabolically labeled with [
35 S]methionine for 1 h. Following change of medium, immunoprecipitation was carried out with anti-XIAP antibody at 0, 2, and 4 h. The amount of labeled XIAP was visualized by SDS-PAGE and autoradiography of the gels. As shown in Fig. 1E , XIAP was almost completely degraded within 4 h in pcDNA3-A2780S cells, whereas the degradation rate was significantly lower in the cells expressing constitutively active AKT2. These data suggest that Akt promotes increased levels of XIAP in A2780S cells by protecting the protein from degradation.
Because the members of IAP family are transcriptionally regulated by NFB pathway (16) and ectopic expression of Akt activates NFB cascade (25, 26) , we further examined whether Akt induces XIAP translation and/or transcription. HEK293 cells were transfected with increasing amount of constitutively active Akt. Western and Northern blot analyses showed that ectopic expression of constitutively active Akt did not induce XIAP at protein and mRNA levels (Fig. 2, A and B) , suggesting that Akt rescuing cisplatin-down-regulated XIAP is not resulted from up-regulation of XIAP at translational/transcriptional level.
Recent reports have demonstrated that mitochondria released Omi/HtrA2 cleavages IAP family proteins, including c-IAP1 and XIAP, during the apoptosis (27, 28) . As cisplatin induces programmed cell death via mitochondrial pathway (11, 22) , we next examined the possible involvement of Omi in cisplatin-induced XIAP degradation. A2780S cells were stably transfected with Bcl2, which is known to stabilize mitochondria in response to cisplatin treatment (29) . The transfected cells were treated with cisplatin for 12 h. Immunoblotting and TUNEL assay analyses showed that unlike constitutively active Akt, Bcl2 only protected XIAP from cisplatin-induced down-regulation at about 20% even though it significantly rescued cisplatin-caused apoptosis (Fig. 2C) . A second possibility of cisplatin-induced XIAP degradation is via either caspase or proteasome pathway. To this end, A2780S cells were treated with cisplatin together with or without caspase inhibitor Z-VAD-fmk or proteasome inhibitor MG132 and/or lactacystin. As shown in Fig. 2D , the XIAP degradation was significantly inhibited by proteasome inhibitors but not by Z-VAD-fmk. These data indicate that the XIAP degradation induced by cisplatin is primarily through proteasome pathway.
Akt Inhibits Autoubiquitination and Cisplatin-induced Ubiquitination of XIAP-XIAP has been shown to possess E3 ubiquitin ligase activity, which is responsible for its autoubiquitination and ubiquitination in response to apoptotic stimuli (16, 21, 29) . To examine whether Akt inhibits autoubiquitination of XIAP, HEK293 cells were transfected with Myc-tagged ubiquitin together with or without constitutively active Akt (MyrAkt). Consistent with previous reports, ectopic expression of ubiquitin induces autoubiquitination of XIAP and its degradation in a manner sensitive to proteasome inhibitor MG132 (22, 29) . Ectopic expression of constitutively active Akt significantly inhibited ubiquitin-induced autoubiquitination of XIAP (Fig.  3A) and prevented proteasome-mediated degradation of XIAP (Fig. 3B) .
We next determined the effects of Akt on cisplatin-induced XIAP ubiquitination. HEK293 and A2780S cells were transfected with FLAG-XIAP and Myc-ubiquitin together with constitutively active or wild type Akt and then treated with cisplatin. Ubiquitination of XIAP was assayed by immunoprecipitation and immunoblotting after 12 h of the treatment. As shown in Fig. 3 , C and D, cisplatin induces ubiquitination of XIAP that was significantly inhibited by expression wild type or/and constitutively active Akt. Taken together, we conclude that Akt stabilizes XIAP by inhibition of its autoubiquitination/ubiquitination.
Akt Phosphorylates and Interacts with XIAP-The fact that Akt regulates XIAP expression at a post-translation level suggests that XIAP may be a substrate of Akt. Indeed, protein sequence analysis revealed a consensus Akt phosphorylation sequence (RXRXXS/T) at residue serine 87 of XIAP, which is contained within the baculovirus-inhibitor-of-apoptosis-repeat 1 (BIR1) domain (Fig. 4A) . To examine whether Akt phosphorylates XIAP, COS7 cells were co-transfected with FLAG-XIAP and constitutively active Akt1 and AKT2. After 36 h of transfection, cells were labeled with [ 32 P]orthophosphate for 3 h. Western blot analysis of FLAG-XIAP immunoprecipitates showed that both constitutively active Akt1 and AKT2 increase phosphorylation levels of XIAP as compared with cells transfected with XIAP and pcDNA3 vector (Fig. 4B) . To examine whether Akt phosphorylates endogenous XIAP, HEK293 cells were either transfected with constitutively active AKT2 or serum-starved and then treated with LY294002 or vehicle (Me 2 SO) prior to insulin stimulation. Endogenous XIAP was immunoprecipitated with anti-XIAP antibody, and the immunoprecipitates were subjected to immunoblotting analysis with anti-Akt substrate antibody. As shown in Fig. 4B , insulin and Akt2 induced phosphorylation of endogenous of XIAP. The phosphorylation induced by insulin was partially inhibited by phosphatidylinositol 3-OH-kinase inhibitor LY294002, suggesting that insulin also induce other kinase(s), in addition to Akt, to phosphorylate XIAP. To determine whether Akt phosphorylates XIAP at residue of sering-87, we generated GST fusion proteins of wild type XIAP and XIAP-S87A, which was created by converting serine 87 residue into alanine. In vitro Akt kinase assay was carried out using the GST-XIAP and -XIAP-S87A fusion proteins as substrates. Repeated experiments revealed that Akt1 and AKT2 can efficiently phosphorylate wild type XIAP but not XIAP-S87A (Fig. 4C) . These data indicate that XIAP is a potential physiological substrate of Akt kinase.
A number of Akt substrates have been shown to interact with Akt, which include IKK␣, tuberin, and apoptosis signal-regulating kinase-1 (7, 10, 11) . We therefore examined whether XIAP physically associates with Akt. HEK293 cells were cotransfected with HA-tagged Akt1, AKT2, and FLAG-XIAP. Immunoprecipitation was carried out with anti-HA and immunoblot of the immunoprecipitates was detected with anti-FLAG antibody or vice versa. As shown in Fig. 4 , D and E, both Akt1 and AKT2 interact with XIAP. The binding affinity between AKT2 and XIAP is higher than that of Akt1 and XIAP. Furthermore, an endogenous protein-protein interaction between XIAP and Akt was also detected in HEK293 cells (Fig. 4F and  data not shown) .
Akt Inhibition of XIAP Ubiquitination/Degradation Depends on Phosphorylation-As demonstrated above, ectopic expression of Akt efficiently phosphorylates serine 87 of XIAP and inhibits XIAP ubiquitination and degradation. We next performed experiments to determine whether phosphorylation of XIAP at serine 87 accounts for the protective effect of Akt on XIAP ubiquitination/degradation. To test this hypothesis, Akt nonphosphorylatable (XIAP-S87A) and phosphomimic (XIAP-S87D) forms of XIAP were created and their capacity of autoubiquitination and cisplatin-induced ubiquitination was examined in HEK293 and A2780S cells, respectively. As shown in Fig. 5A , nonphosphorylatable XIAP-S87A and wild type XIAP underwent autoubiquitination when the cells were co-transfected with ubiquitin. Furthermore, autoubiquitination levels of phosphomimic XIAP-S87D decreased as compared with nonphosphorylatable and wild type XIAP. Unlike wild type XIAP (also seen in Fig. 3B ), however, constitutively active Akt did not exhibit effects on either XIAP-S87A or XIAP-S87D autoubiquitination (Fig. 5A) . Taken together, these results provide strong evidence that phosphorylation of XIAP at serine 87 occurs in cells, and this modification results in protection of XIAP from autoubiquitination.
To examine the impact of Akt phosphorylation of XIAP on cisplatin-induced ubiquitination and degradation of XIAP, A2780S cells were transfected with XIAP-S87A and XIAP-S87D. Following treatment with cisplatin for 12 h, we found that nonphosphorylatable XIAP-S87A was ubiquitinated in a cisplatin-dependent manner, whereas phosphomimic XIAP-S87D was resistant to cisplatin-induced ubiquitination (Fig.  5B) . Accordingly, we also observed significantly reduced protein levels of nonphosphorylatable XIAP-S87A but not phosphomimic XIAP-S87D in response to cisplatin treatment (Fig.  5C) . From these studies, we conclude that Akt inhibition of cisplatin-induced ubiquitination and degradation of XIAP are also done in a phosphorylation-dependent manner.
Effect of Akt Phosphorylation of XIAP on Its Antiapoptotic Function-As XIAP exhibits its anti-apoptotic effects by inhibiting caspase-3 and caspase-9, and our data show Akt inhibition of ubiquitination/degradation of XIAP by phosphorylation of XIAP, we next examined whether the phosphorylation of XIAP affects its antiapoptotic function. Wild type XIAP, nonphosphorylatable XIAP-S87A, and phosphomimic XIAP-S87D were introduced into A2780S cells. Following cisplatin treatment for 24 h, caspase-3 activity and apoptosis were analyzed. As shown in Fig. 5D , ectopic expression of all three forms of XIAP inhibits cisplatin-induced apoptosis and caspase-3 activity as compared with the cells transfected with pcDNA3 vector alone. However, nonphosphorylatable XIAP-S87A exhibited significantly lower antiapoptotic activity, whereas phosphomimic XIAP-S87D showed relatively higher anti-apoptotic function when compared with wild type XIAP.
To further determine the significance of Akt phosphorylation/stabilization of XIAP in Akt survival signaling, Myr-AKT2-and pcDNA3-A2780S cells were transfected or infected with siRNA or adenovirus of antisense of XIAP and then treated with cisplatin or vehicle (Me 2 SO) for 12 h. Immunoblotting analysis showed that expression of XIAP was significantly inhibited by siRNA and antisense of XIAP (Fig. 6, A and  C) . The suppression of XIAP expression induces apoptosis in both AKT2-and pcDNA3-A2780S cells as compared with the cells treated with control siRNA or adenovirus of LacZ, which is consistent with recent reports in other cancer cells (30, 31) . Furthermore, siRNA and adenovirus of antisense of XIAP largely abrogated constitutively active AKT2 protection of the cells from cisplatin-induced apoptosis (Fig. 6, B and D) . These data indicate that XIAP is an important survival molecule and mediates Akt-induced cell survival and cisplatin resistance in A2780S cells. DISCUSSION XIAP is regulated at transcriptional and post-transcriptional levels. Activation of NFB pathway induces RNA level of XIAP (16, 32) . Since it possesses E3 ubiquitin ligase activity, XIAP can be autoubiquitinated and ubiquitinated in response to DNA damage, including treatment with chemotherapeutic agents (16, 21, 29) . Recent studies showed that XIAP is cleaved by the mature serine protease Omi/HtrA2, a proapoptotic protein released from the mitochondria into the cytosol during apoptosis (27, 28) . In this study, we demonstrate that the phosphorylation of XIAP by Akt regulates its ubiquitination and degradation. Akt, including Akt1 and AKT2, interacts with and phosphorylates XIAP, leading to inhibition of XIAP autoubiquitination and cisplatin-induced ubiquitination. We fur- ther demonstrate that Akt phosphorylates serine 87 of XIAP and that the inhibition of ubiquitination/degradation of XIAP depends on phosphorylation at this site. In addition, we have shown that Akt regulation of XIAP is not at transcriptional level ( Figs. 1 and 2 ). However, we cannot exclude the possibility of Akt regulation of XIAP at translational level as Akt has been shown to activate mTOR/p70 S6K pathway (7). Nevertheless, these data indicate that the phosphorylation by Akt may be one of key mechanisms regulating XIAP levels and function in cells.
Accumulated evidence shows that Akt pathway exerts an anti-apoptotic action by regulation of molecules at both preand post-mitochondrial levels. The proapoptotic protein Bad has been shown to be a major target of Akt at the pre-mitochondrial level (13) . However, the target(s) of Akt at the postmitochondrial level have not been well documented, although a study demonstrated Akt phosphorylation and inhibition of caspase-9 (14) . We show in this report that Akt interacts with and phosphorylates XIAP resulting in inhibition of caspase-3 activity and apoptosis in response to cisplatin treatment. Unlike caspase-9, in which Akt phosphorylation consensus site only exists in human (14, 33) , the phosphorylation site of XIAP ( 82 RHRKVS 87 ) is well conserved among human, mouse, and rat (Fig. 4A) . Thus, we conclude that XIAP could be a major target of Akt antiapoptotic function at post-mitochondrial level.
We have previously demonstrated that overexpression and/or activation of Akt contributes to cisplatin resistance in human ovarian cancer (24) . XIAP content has been shown to be a determinant of cisplatin resistance in human ovarian cancer (21, 22) . In this study, we have observed that cisplatin decreases XIAP protein content in A2780S cells without a significant change in XIAP mRNA level ( Figs. 1 and 2 ) and suggest that XIAP gene transcription is not involved in XIAP downregulation by cisplatin. Furthermore, ectopic expression of zinc RING finger domain deleted mutant XIAP, in which ubiquitin ligase activity was disrupted, rendered cells more resistant to cisplatin as compared with expression of wild type XIAP (34) . These findings indicate that XIAP degradation is an important mechanism to regulate the steady-state XIAP and determine the sensitivity to cisplatin in human ovarian cancer cells. We demonstrate in this report that ectopic expression of constitutively active Akt protects XIAP from ubiquitination and degradation induced by cisplatin. Furthermore, phosphomimic XIAP-S87D is more resistant to ubiquitination/degradation induced by cisplatin than wild type XIAP. Conversely, the nonphosphorylatable XIAP-S87A shows increased ubiquitination relative to wild type XIAP (Fig. 5) . In addition, suppression of XIAP by siRNA or antisense of XIAP abrogated Akt-induced cisplatin resistance and cell survival (Fig. 6 ). These data indicate that Akt stabilization of XIAP could be a major mechanism accounting for Akt-induced cisplatin resistance in human ovarian cancer cells.
In summary, the data presented here demonstrate for the first time that XIAP is regulated by phosphorylation. Akt phosphorylates XIAP at residue serine 87 in vitro and in vivo and interacts with XIAP at physiological protein concentration. The phosphorylation of XIAP at serine 87 by Akt results in inhibition of its autoubiquitination and ubiquitination and thus confers resistance to cisplatin-induced XIAP degradation, caspase-3 activation, and apoptosis. These results suggest that XIAP, in addition to Bad, is a major physiological substrate of Akt in the regulation of apoptosis, especially at the post-mitochondrial level. 
